Squalene synthase inhibitors
- 1 July 2003
- journal article
- editorial
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (5) , 881-882
- https://doi.org/10.1038/sj.bjp.0705331
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Ezetimibe: The First in a Novel Class of Selective Cholesterol-Absorption InhibitorsHeart Disease, 2002
- Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patientsAtherosclerosis, 2002
- BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasisJournal of Lipid Research, 2002
- Sterols and Isoprenoids: Signaling Molecules Derived from the Cholesterol Biosynthetic PathwayAnnual Review of Biochemistry, 1999
- Inhibition of Cholesterol Synthesis by Squalene Synthase Inhibitors Does Not Induce Myotoxicityin VitroToxicology and Applied Pharmacology, 1997
- HMG CoA Reductase Inhibitor-Induced Myotoxicity: Pravastatin and Lovastatin Inhibit the Geranylgeranylation of Low-Molecular-Weight Proteins in Neonatal Rat Muscle Cell CultureToxicology and Applied Pharmacology, 1997
- Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemiaAtherosclerosis, 1996
- Cholesterol and Coronary Heart DiseaseJAMA, 1986
- Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countriesThe American Journal of Cardiology, 1986
- Cataracts in Patients Treated with TriparanolPublished by American Medical Association (AMA) ,1962